# Spesolimab in Pyoderma Gangrenosum

> **NCT06092216** · PHASE2 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 5 (actual)

## Conditions studied

- Pyoderma Gangrenosum

## Interventions

- **DRUG:** Spesolimab

## Key facts

- **NCT ID:** NCT06092216
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-23
- **Primary completion:** 2025-01-14
- **Final completion:** 2025-01-14
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The funding sponsor terminated our study and will conduct a multicenter national study in its place.
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06092216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06092216, "Spesolimab in Pyoderma Gangrenosum". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06092216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*